spacer
home > ebr > summer 2018 > enhancing analysis
PUBLICATIONS
European Biopharmaceutical Review

Enhancing Analysis

Monoclonal antibodies (mAbs) are a prominent class of protein biotherapeutics because they have demonstrated outstanding efficacy in the treatment of both acute and chronic disease, with several targeted mAb drugs reaching ‘blockbuster’ status in recent years (1). This uptake is due to their many advantages over traditional small molecules, including high specificity, favourable toxicity profile, and long serum half-life (2). However, mAbs are known to form aggregates, either during fermentation, product purification, in storage, or through mishandling prior to patient administration. The formation of mAb aggregates can jeopardise both the efficacy and safety of biotherapeutics in the clinic. Specifically, the aggregation of mAb monomers to dimers, trimers, or higher order structures can be problematic for two key reasons:

• Aggregates can cause a decrease in product efficiency by lowering its effective concentration

• Aggregation can expose normally unexposed epitopes, which lead to increased immunogenicity

For high molecular weight species (HMWS) of aggregates, the primary concern is their potential to increase product immunogenicity, while low molecular weight species (LMWS) can have decreased activity or a reduced serum half-life due to missing crystallisable (Fc) regions or antigen-binding (Fab) fragments (3). Therefore, monitoring aggregate formation throughout the production process is essential to ensure the safety and efficacy of the mAb and to gain regulatory approval.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Amy Farell is the applications development team leader at the the National Institute for Bioprocessing Research and Training (NIBRT).

Dr Sara Carillo completed her PhD in chemical sciences in 2013 at the University of Naples Federico 2, Italy. She focused on the structural characterisation of polysaccharides and glyco-conjugates from gramnegative bacteria. In 2015, Sara joined Dr Jonathan Bones’ research group at the NIBRT, working on the understanding of the effects of extractables and leachables from single-use bioreactors on Chinese hamster ovary cells N-glycome. She is now working at the NIBRT in collaboration with Thermo Fisher Scientific for the development of new analytical approaches in biopharmaceuticals.

Dr Jonathan Bones received his PhD in analytical chemistry from Dublin City University, Ireland, in 2007. He then moved to the NIBRT within the GlycoScience Laboratory. In 2010, Jonathan was appointed the John Hatsopoulos Research Scholar within the Barnett Institute of Chemical and Biological Analysis at Northeastern University, Boston, before returning to NIBRT in 2012 to become the Principal Investigator of the NIBRT Characterisation and Comparability Laboratory and an Associate Professor at the School of Chemical and Bioprocess Engineering at University College Dublin.
spacer
Dr Amy Farell
spacer
spacer
spacer
Sara Carillo
spacer
spacer
spacer
Dr Jonathan Bones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Completes Acquisition of Sherpa Clinical Packaging

Philadelphia, USA – October 2, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced the completion of its acquisition of Sherpa Clinical Packaging (Sherpa).
More info >>

White Papers

The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation

BioPharmaSpec

1. Introduction As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >>

 
Industry Events

Digital Medicine & Medtech Showcase 2019

8-9 January 2019, Parc 55 San Francisco - a Hilton Hotel

The Digital Medicine and Medtech Showcase is the dedicated home for the digital health and medtech communities during Biotech Showcase™ and one of the healthcare industry’s biggest weeks. Taking place January 8–9, Digital Medicine & Medtech Showcase includes two days of networking opportunities, curated presentations, specialized sessions, one-to-one meetings scheduled by partneringONE®, and full access to Biotech Showcase.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement